Skip to main content
Erschienen in: Hepatology International 5/2016

08.03.2016 | Original Article

HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes

verfasst von: Tien Huey Lim, Edward Gane, Chris Moyes, Barry Borman, Chris Cunningham

Erschienen in: Hepatology International | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

HBsAg seroclearance is the most desired endpoint in chronic hepatitis B (CHB) but occurs uncommonly. Recent studies have shown baseline HBsAg levels to be predictive of HBsAg loss up to 10 years. We report the 28-year rates of HBsAg loss and outcomes in the Kawerau study cohort from New Zealand, and assess the predictive value of baseline HBsAg levels to predict long-term HBsAg loss.

Methods

The 1984 Kawerau community study identified 572 CHB patients, followed up for 28 years (41 % HBeAg-positive, median age 17 years, range 1–71 years). In 2012, surviving individuals attended a local clinic for an interview, blood tests and transient elastography.

Results

384/218 (74 %) surviving individuals attended the clinic in 2012. Spontaneous HBsAg loss occurred in 145 (33 %) after 12,702 person-years of follow-up (1.14 per 100 person-years). Liver stiffness measurements were significantly lower if HBsAg loss occurred <50 years (mean 6.1 kPa) versus >50 years (mean 11.6 kPa), p = 0.0002. No HCC occurred following HBsAg loss (median follow-up 72 months). Predictors of HBsAg loss were older age and lower baseline HBsAg level (HR for HBsAg loss at 28 years 2.7 (95 % CI 1.7–4.2), 6.7 (95 % CI 3.9–11.4) and 9.4 (95 % CI 5.2–16.9), respectively, for HBsAg 1000–9999, 100–999 and <100 IU/mL compared to HBsAg >10,000 IU/mL at baseline, (p < 0.0001). Baseline HBsAg was a superior predictor of HBsAg loss compared to HBV DNA at all time-points: AUROC at 15 years: 0.87 (95 % CI 0.82–0.93) versus 0.73 (95 % CI 0.66–0.80) (p < 0.0001) and AUROC at 28 years: 0.74 (95 % CI 0.69–0.79) versus 0.67 (95 % CI 0.62–0.72) (p = 0.0007). The optimal cut-off HBsAg level to predict HBsAg seroclearance at 28 years is HBsAg <10,000 IU/mL (sensitivity 72 %, specificity 64 %, NPV 88 %).

Conclusions

Rates of HBsAg loss in our community cohort were high, and occurred earlier than previously reported. Earlier HBsAg loss was associated with less severe liver fibrosis. Baseline HBsAg level was a good predictor of long-term HBsAg loss up to 28 years and superior to HBV DNA.
Literatur
1.
Zurück zum Zitat Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1997;26:1338–1342CrossRefPubMed Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1997;26:1338–1342CrossRefPubMed
2.
Zurück zum Zitat Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005;42:188–194CrossRefPubMed Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, et al. long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005;42:188–194CrossRefPubMed
3.
Zurück zum Zitat Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334(22):1422–1427CrossRefPubMed Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334(22):1422–1427CrossRefPubMed
4.
Zurück zum Zitat Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145(11):1039–1047CrossRefPubMed Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145(11):1039–1047CrossRefPubMed
5.
Zurück zum Zitat Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531CrossRefPubMed Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–1531CrossRefPubMed
6.
Zurück zum Zitat Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971–975CrossRefPubMed Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3):971–975CrossRefPubMed
7.
Zurück zum Zitat Yuen MF, Hui CK, Cheng CC, et al. long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect of hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139–145CrossRefPubMed Yuen MF, Hui CK, Cheng CC, et al. long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect of hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology. 2001;34:139–145CrossRefPubMed
8.
Zurück zum Zitat Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187–1192CrossRefPubMed Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187–1192CrossRefPubMed
9.
Zurück zum Zitat Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13(4):627–631CrossRefPubMed Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13(4):627–631CrossRefPubMed
10.
Zurück zum Zitat McMahon BJ, Holck P, Bulkow L, Snowball M. Serological and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135(9):759–768CrossRefPubMed McMahon BJ, Holck P, Bulkow L, Snowball M. Serological and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135(9):759–768CrossRefPubMed
11.
Zurück zum Zitat Kim JH, Lee JH, Park SJ, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology. 2008;55:576–581 Kim JH, Lee JH, Park SJ, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology. 2008;55:576–581
12.
Zurück zum Zitat Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51(5):1531–1537CrossRefPubMed Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology. 2010;51(5):1531–1537CrossRefPubMed
13.
Zurück zum Zitat De Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118(3):191–194CrossRefPubMed De Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993;118(3):191–194CrossRefPubMed
14.
Zurück zum Zitat Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histology and clinical aspects. Hepatology. 2004;39:1694–1701CrossRefPubMed Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histology and clinical aspects. Hepatology. 2004;39:1694–1701CrossRefPubMed
15.
Zurück zum Zitat Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;19:e9–e15 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;19:e9–e15
16.
Zurück zum Zitat Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peg-interferon alpha-2b for HbeAg-positive chronic hepatitis B: HbsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297–303CrossRefPubMed Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peg-interferon alpha-2b for HbeAg-positive chronic hepatitis B: HbsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006;101:297–303CrossRefPubMed
17.
Zurück zum Zitat Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–482CrossRefPubMed Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474–482CrossRefPubMed
18.
Zurück zum Zitat Lim TH, Gane E, Moyes C, Borman B, Cunningham C. Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study. Gut. 2015;64(6):966–72CrossRefPubMed Lim TH, Gane E, Moyes C, Borman B, Cunningham C. Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study. Gut. 2015;64(6):966–72CrossRefPubMed
19.
Zurück zum Zitat Milne A, Allwood GK, Moyes CD, et al. A seroepidemiological study of the prevalence of hepatitis B infections in a hyperendemic New Zealand Community. Int J Epidmiol. 1987;16:84–90CrossRef Milne A, Allwood GK, Moyes CD, et al. A seroepidemiological study of the prevalence of hepatitis B infections in a hyperendemic New Zealand Community. Int J Epidmiol. 1987;16:84–90CrossRef
20.
Zurück zum Zitat Diminsky D, Moav N, Gorecki M, Barenholz Y. Physical, chemical and immunological stability of CHO–derived hepatitis B surface antigen (HBsAg) particles. Vaccine. 1999;18(1–2):3–17CrossRefPubMed Diminsky D, Moav N, Gorecki M, Barenholz Y. Physical, chemical and immunological stability of CHO–derived hepatitis B surface antigen (HBsAg) particles. Vaccine. 1999;18(1–2):3–17CrossRefPubMed
21.
Zurück zum Zitat Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73CrossRefPubMed Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73CrossRefPubMed
22.
Zurück zum Zitat Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686CrossRefPubMed Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686CrossRefPubMed
23.
Zurück zum Zitat Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931CrossRefPubMed Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931CrossRefPubMed
24.
Zurück zum Zitat Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, et al. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels 3 years before HBsAg seroclearance. Hepatology. 2012;56:812–819CrossRefPubMed Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, et al. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels 3 years before HBsAg seroclearance. Hepatology. 2012;56:812–819CrossRefPubMed
26.
Zurück zum Zitat Chan HLY, Wong GLH, Tse CH, Chan HY, Wong VWS. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408–413CrossRefPubMed Chan HLY, Wong GLH, Tse CH, Chan HY, Wong VWS. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408–413CrossRefPubMed
27.
Zurück zum Zitat Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58:853–860CrossRefPubMed Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol. 2013;58:853–860CrossRefPubMed
28.
Zurück zum Zitat Chang MH, Chiu YC, Wu JF, Lin CY, Ni YH, Chen HL et al. Spontaneous clearance of hepatitis B surface antigen during the natural history of chronic hepatitis B virus infection. Hepatology 2011;54:Abstr 731 Chang MH, Chiu YC, Wu JF, Lin CY, Ni YH, Chen HL et al. Spontaneous clearance of hepatitis B surface antigen during the natural history of chronic hepatitis B virus infection. Hepatology 2011;54:Abstr 731
29.
Zurück zum Zitat Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2012;10:297–302CrossRefPubMed Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2012;10:297–302CrossRefPubMed
30.
Zurück zum Zitat Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141(2):517–525CrossRefPubMed Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141(2):517–525CrossRefPubMed
31.
Zurück zum Zitat Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with low viral load. Hepatology. 2012;55:68–76CrossRefPubMed Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with low viral load. Hepatology. 2012;55:68–76CrossRefPubMed
32.
Zurück zum Zitat Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089CrossRefPubMed Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089CrossRefPubMed
33.
Zurück zum Zitat Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28(1):231–236CrossRefPubMed Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28(1):231–236CrossRefPubMed
34.
Zurück zum Zitat Yuen MF, Wong DKH, Fung J, Ip P, But D, Hung I, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192–1199CrossRefPubMed Yuen MF, Wong DKH, Fung J, Ip P, But D, Hung I, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192–1199CrossRefPubMed
35.
Zurück zum Zitat Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol. 1998;93:896–900CrossRefPubMed Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol. 1998;93:896–900CrossRefPubMed
36.
Zurück zum Zitat Dragosics B, Ferenci P, Hitchman E, et al. long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7:302–306CrossRefPubMed Dragosics B, Ferenci P, Hitchman E, et al. long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology. 1987;7:302–306CrossRefPubMed
37.
Zurück zum Zitat Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–434CrossRefPubMed Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–434CrossRefPubMed
38.
Zurück zum Zitat Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–690CrossRefPubMed Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–690CrossRefPubMed
39.
Zurück zum Zitat Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172CrossRefPubMed Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172CrossRefPubMed
40.
Zurück zum Zitat Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98:1166–1175CrossRefPubMedPubMedCentral Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98:1166–1175CrossRefPubMedPubMedCentral
Metadaten
Titel
HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes
verfasst von
Tien Huey Lim
Edward Gane
Chris Moyes
Barry Borman
Chris Cunningham
Publikationsdatum
08.03.2016
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 5/2016
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9709-6

Weitere Artikel der Ausgabe 5/2016

Hepatology International 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.